Why Oral GLP-1 Manufacturing Capacity Decides The Leader

Introduction

Everyone in the obesity and diabetes space has been talking about oral GLP-1s as a convenience breakthrough. No more needles, no more cold-chain storage, no more injection anxiety keeping patients from starting or staying on treatment. 

That story is true, and it matters. But it's not the story that actually determines which oral GLP-1 wins, how fast it scales, or which company controls the next phase of this market. That story is written in factories, fermenters, and API supply chains, months and years before it ever shows up in a clinical trial readout.

Two oral GLP-1s have now reached the U.S. market. Novo Nordisk's oral Wegovy pill was approved in December 2025 and launched in early January 2026. Eli Lilly's orforglipron, sold under the brand name Foundayo, followed close behind with FDA approval on April 1, 2026. 

On paper, both are once-daily pills targeting the same receptor for the same conditions. Underneath, they're built from almost entirely different manufacturing playbooks, and that difference is going to shape this market far more than any head-to-head efficacy comparison.

This isn't a small distinction buried in a technical appendix. It's the difference between a company that can meet demand on day one and a company that spends its first year of launch apologizing for shortages. 

The industry has already lived through one painful version of this lesson with injectable GLP-1s, where years of intermittent stockouts had far less to do with clinical uncertainty and far more to do with how hard it is to scale complex biologic manufacturing fast enough to match a demand curve nobody fully predicted. Oral GLP-1s were supposed to sidestep that problem. As it turns out, they only partly do.

Why The Molecule Itself Is The Real Starting Point?

Here's the detail that gets buried under the marketing headlines: Novo's oral Wegovy and Lilly's Foundayo aren't the same kind of drug wearing different packaging. They're built from fundamentally different chemistry, and that choice was made years before either company thought about pricing or launch dates.

• Oral Wegovy Is A Peptide: Semaglutide is the same active molecule used in the injectable version, just reformulated for oral absorption with the help of an ingredient called SNAC. Peptides are large, complex molecules that are hard for the digestive system to absorb intact, which is why the pill requires patients to take it fasting, thirty minutes before eating or drinking anything other than water.

• Foundayo Is A Small Molecule: Orforglipron is a non-peptide compound at roughly 600 daltons, chemically closer to a conventional tablet drug like ibuprofen than to a biologic. It can be taken any time of day, with or without food, with no fasting rules at all.

That single chemistry decision cascades into almost everything downstream. A peptide requires a manufacturing process built around fermentation, complex purification, and specialized handling, the same demanding infrastructure used for injectable GLP-1s. 

A small molecule can be produced using conventional pharmaceutical chemistry, the kind of manufacturing base the industry has decades of experience scaling quickly and cheaply. This is why one industry analysis flagged orforglipron's manufacturing profile as a genuine competitive advantage, not just a formulation footnote.

It's worth pausing on why this matters so much more for GLP-1s than it would for an average small-molecule drug. Peptide manufacturing has historically been one of the more fragile parts of the biopharma supply chain, dependent on a relatively small number of specialized facilities capable of running large-scale fermentation and purification at pharmaceutical-grade purity. 

When demand for a peptide-based drug spikes the way it has for GLP-1s over the past few years, that fragility turns into a genuine bottleneck almost overnight, because you can't simply contract out to a generic chemical plant the way you often can with a conventional small molecule. 

Orforglipron's chemistry sidesteps that specific fragility, which is exactly why its manufacturing profile has become such a talking point among analysts covering the category, even before its clinical data was fully public.

The Manufacturing Advantage Nobody Puts On A Slide

If you strip away the clinical marketing, the real competitive question in oral GLP-1s right now is this: which manufacturing approach can produce enough pills, fast enough, at a low enough cost, to actually meet the size of the demand curve. A few things make this genuinely different from the injectable era that came before it.

1) Both oral formats skip the sterile fill-finish bottleneck. Injectable GLP-1s require aseptic filling, vial sterilization, and often lyophilization, each step demanding its own qualified production line with long validation timelines. Oral tablets avoid that entire category of bottleneck, which is part of why both companies were able to move from approval to launch so quickly.

2) But the two oral drugs still diverge sharply from there Semaglutide's peptide backbone means Novo still needs the same fermentation and purification capacity it built for injectable Wegovy and Ozempic, just redirected. The company has reportedly begun shifting semaglutide API production toward lower-cost, high-volume facilities specifically built for oral-scale output, a real infrastructure pivot rather than a simple relabeling exercise.

3) Orforglipron's small-molecule status should, in theory, make it easier to scale. Yet Lilly is still building a dedicated plant in Huntsville, Alabama specifically for orforglipron, which tells you something important: even a manufacturing-friendly molecule needs serious, purpose-built capacity when the addressable market is this large. Convenience on paper doesn't remove the need for real factories.

4) Lilly has built roughly $1.5 billion in pre-launch inventory for orforglipron alone. That's not a modest hedge. It's a direct signal that Lilly expected demand to outrun typical production ramp timelines from day one, and chose to front-load supply rather than risk a repeat of the shortages that defined the injectable GLP-1 era.

5) Government policy is now explicitly rewarding domestic manufacturing commitments. Both companies received Commissioner's National Priority Vouchers tied partly to establishing U.S.-based manufacturing, which compresses FDA review timelines from ten to twelve months down to just one or two. In other words, the regulatory pathway itself is now partly a function of where and how fast a company can build capacity.

The Capacity Race Behind The Scenes

Neither company is treating this as a one-plant problem, and understanding their build-out strategies says more about who's likely to lead this market over the next few years than any Phase 3 data readout does.

Lilly's approach has been to add manufacturing capacity sequentially across multiple sites, layering new buildings onto its existing GLP-1 footprint in Indiana while also standing up entirely new sites in Pennsylvania, Texas, and Alabama. 

That staggered strategy lets the company bring capacity online in stages rather than waiting for one mega-facility to be fully validated before producing a single pill. 

For a more complex peptide like retatrutide, Lilly has gone as far as hiring dedicated peptide purification specialists early and running parallel pilot campaigns, essentially derisking the scale-up before it becomes a bottleneck.

Novo Nordisk took a different route entirely: it acquired the capacity rather than building all of it organically. Its $16.5 billion purchase of Catalent, completed in 2024, handed Novo direct control over three fill-finish facilities in Italy, Belgium, and the United States. 

That deal was aimed primarily at solving injectable production constraints, but it illustrates the broader principle at play across this entire category: owning manufacturing infrastructure, rather than renting it through a contract manufacturer, has become a genuine strategic asset in this market, not just an operational convenience.

Across the industry, several manufacturing shifts are converging at once:

• 1) Continuous manufacturing is starting to replace traditional batch-by-batch production, cutting the time and variability involved in scaling a new formulation.

• 2) Aqueous peptide synthesis is emerging as a way to reduce the solvent-heavy, resource-intensive steps that have historically made peptide production slow and expensive.

• 3) Vertical integration is becoming the norm rather than the exception, with both major players choosing to own more of their supply chain directly instead of depending on external CDMOs for critical steps.

Novo and Lilly aren't the only ones racing to close the GLP-1 manufacturing gap, a growing CDMO network is stepping in too.
→ Read: GLP-1 Manufacturing Capacity: Where Novo, Lilly, and CDMOs Stand Today

Why Does This Determine The Competitive Outcome, Not Just The Supply Chain?

It's worth being direct about why this matters commercially and not just operationally. The oral GLP-1 market is projected to grow from roughly $9.2 billion in 2026 to more than $137 billion by 2035, a compound annual growth rate above 35%. 

Semaglutide currently holds a dominant 71% share of the oral peptide segment, largely on the strength of Novo's first-mover position and existing brand trust. 

But orforglipron's more patient-friendly dosing profile, no fasting, no timing restrictions, is exactly the kind of advantage that becomes real only if Lilly can manufacture and distribute at the volume needed to compete for that same patient base.

This is where the manufacturing story and the clinical story finally meet. A drug with a better convenience profile and reasonable trial data still loses the year if the company behind it can't fill pharmacy shelves consistently. 

The injectable GLP-1 era already proved this once, with years of intermittent shortages driven almost entirely by production constraints rather than demand uncertainty or regulatory delay. 

Both companies clearly learned that lesson, which is exactly why pre-launch inventory building, sequential plant construction, and acquisition-driven capacity have all become standard playbook moves rather than one-off decisions.

Price adds another layer. A recent agreement between the current administration and both major manufacturers brought the monthly price of GLP-1 weight-loss drugs down from over $1,000 to as low as $245 for eligible patients, with Lilly pricing orforglipron in the $149 to $399 range depending on dose and channel. 

Pricing at that level only works at scale if the underlying manufacturing cost structure supports it, which circles back to exactly the small-molecule-versus-peptide cost dynamic driving each company's factory decisions in the first place.

Semaglutide's manufacturing story ties back to its origins, worth understanding how the molecule itself scaled into a blockbuster.

→ Read: Ozempic: Uses, Popularity, and Pharma Trends

What Does This Means For The Rest Of The Industry?

The manufacturing dimension of oral GLP-1s isn't just a two-company story. It's reshaping deal-making across the entire biopharma landscape. More than $47 billion in GLP-1-related deal value has been committed since 2023, with the pace accelerating sharply, from $8.4 billion in 2024 to over $20 billion in 2025, and continuing into 2026. 

Much of that capital is chasing the same insight driving Lilly and Novo's manufacturing bets: injectable GLP-1 leadership is essentially locked between the two incumbents, but the oral small-molecule wave represents a genuine entry point for everyone else. 

Deals like AstraZeneca's roughly $18.5 billion partnership with CSPC and Pfizer's roughly $10 billion acquisition of Metsera reflect bets on the broader metabolic platform, not just a single molecule, and manufacturing feasibility is a core part of what makes those bets viable in the first place.

For companies entering this space now, whether through partnership, acquisition, or internal development, the practical takeaway is straightforward: a promising oral GLP-1 candidate is not a finished asset until there's a credible, fundable, scalable manufacturing plan behind it. 

Investors and partners evaluating these deals are increasingly asking manufacturing questions as early as they ask efficacy questions, because the last three years have made it painfully clear that clinical success without production capacity just creates a very expensive shortage.

The Bottom Line

Oral GLP-1s are being sold to the public as a convenience story: swap the needle for a pill, and adherence goes up. That's a real and important part of the picture. But underneath every approval headline sits a much longer, less visible story about fermentation capacity, purification chemistry, sterile-fill bottlenecks that were avoided, factories that had to be built anyway, and billions of dollars in inventory positioned months before a single prescription was written.

The companies winning this category aren't necessarily the ones with the cleanest trial data. They're the ones that treated manufacturing as the actual product decision, made years before launch, rather than an afterthought to be solved once demand showed up. 

As more companies chase the oral GLP-1 opportunity through partnerships and acquisitions, the ones asking hard manufacturing questions before signing the deal are the ones most likely to avoid becoming the next cautionary tale about a great drug nobody could actually get.

FAQs

1) Why Is Manufacturing Important For Oral GLP-1s?

Manufacturing determines how quickly oral GLP-1s can be produced, scaled, and supplied to meet growing patient demand. A strong manufacturing network can also help companies avoid shortages and maintain consistent availability after launch.

2) How Are Oral Wegovy And Foundayo Manufactured Differently?

Oral Wegovy uses peptide-based semaglutide, which requires fermentation and purification. Foundayo uses orforglipron, a small molecule that can be manufactured using conventional pharmaceutical chemistry. This difference can affect production complexity, scalability, costs, and the speed at which supply can be expanded.

3) Does Oral GLP-1 Manufacturing Avoid The Challenges Of Injectable Drugs?

Oral GLP-1s avoid some challenges, such as sterile filling, but peptide-based products can still require complex manufacturing and purification processes. This means switching from injections to tablets does not completely eliminate the supply-chain challenges associated with GLP-1 medicines.

4) Why Does Manufacturing Capacity Matter For GLP-1 Market Competition?

Strong manufacturing capacity helps companies maintain reliable supply, control costs, and respond quickly to rising demand. It can also give manufacturers greater flexibility to support competitive pricing and expand access as the oral GLP-1 market grows.

5) Will Manufacturing Influence The Future Leaders Of The Oral GLP-1 Market?

Yes. Companies with scalable, cost-efficient, and reliable manufacturing networks may have a major advantage as demand for oral GLP-1 treatments grows. Clinical performance and patient convenience will remain important, but the ability to consistently produce and distribute medicines at scale could strongly influence market leadership.